IL33 and familial pancreatic carcinoma: This is supported by the previous finding that IL-33 ligating to its receptor could inhibit GSK-3β that normally regulates the proliferation and survival of pancreatic cancer cells 34, finally leading to attenuation of cancer progression 35.